PRISM MarketView Features Q&A With President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx Addressing Patients With Recurrent Pericarditis

GlobeNewswireDec 19 21:30

HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target

BenzingaNov 20 20:02 · Ratings

Cardiol Therapeutics' CardiolRx Gains Buy Rating on Positive Phase 2 Results and Strong Financial Position

TipRanksNov 20 19:20 · Ratings

CBD-Based Drug Reduces Pericarditis Pain And Inflammation, Shows New Clinical Study

BenzingaNov 20 03:24

Cardiol Therapeutics' Presents Phase II MAvERIC-Pilot Clinical Results In Recurrent Pericarditis Presented At The AHA Scientific Sessions 2024; Marked And Rapid Reductions In Both Pericarditis Pain And Inflammation Maintained Throughout The 26-Week Study

BenzingaNov 19 00:38

Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

newsfileNov 19 00:37